A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in chinese patients with chronic hepatitis B

Key Points

• The study aims to evaluate the effectiveness of pradefovir mesylate compared to tenofovir disoproxil fumarate in treating chronic hepatitis B.
• Randomized, double-blind, phase 3 trial design
• Comparison of pradefovir mesylate and tenofovir disoproxil fumarate
• Conducted with Chinese patients diagnosed with chronic hepatitis B
• Pradefovir mesylate showed comparable effectiveness to tenofovir disoproxil fumarate
• Pradefovir should be regarded as a highly recommended treatment option for chronic hepatitis B patients

Abstract